Publicaciones en colaboración con investigadores/as de Massachusetts General Hospital (9)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Efficacy and acceptability of psychosocial interventions in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence

    Molecular Psychiatry, Vol. 28, Núm. 1, pp. 354-368

  3. Schizophrenia risk conferred by rare protein-truncating variants is conserved across diverse human populations

    Nature genetics, Vol. 55, Núm. 3, pp. 369-376

2022

  1. Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs

    Human Brain Mapping, Vol. 43, Núm. 1, pp. 300-328

  2. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

  3. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe

    The Lancet Psychiatry, Vol. 9, Núm. 1, pp. 46-58

2020

  1. Sensory-to-Cognitive Systems Integration Is Associated With Clinical Severity in Autism Spectrum Disorder

    Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 59, Núm. 3, pp. 422-433

2018

  1. Widespread white matter microstructural differences in schizophrenia across 4322 individuals: Results from the ENIGMA Schizophrenia DTI Working Group

    Molecular Psychiatry, Vol. 23, Núm. 5, pp. 1261-1269

2009

  1. Advantages and disadvantages of combination treatment with antipsychotics. ECNP Consensus Meeting, March 2008, Nice

    European Neuropsychopharmacology, Vol. 19, Núm. 7, pp. 520-532